<DOC>
	<DOCNO>NCT00084344</DOCNO>
	<brief_summary>RATIONALE : High estrogen level may associate dense breast tissue increase risk develop breast cancer . 4-hydroxytamoxifen gel ( substance make tamoxifen break body ) may effective reduce breast density reduce estrogen level few side effect tamoxifen . This may improve quality life ability detect breast cancer screen mammography . PURPOSE : Randomized screening study determine effect 4-hydroxytamoxifen gel breast density , salivary sex steroid ( hormone ) , quality life premenopausal woman .</brief_summary>
	<brief_title>Effect 4-Hydroxytamoxifen Gel Breast Density , Salivary Sex Steroids , Quality Life Premenopausal Women</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect 4-hydroxytamoxifen gel breast density , measure digital mammography , premenopausal woman . - Determine effect gel breast density participant , define BIRADS lexicon . Secondary - Determine effect gel salivary sex steroid level participant . - Determine effect gel quality life participant . OUTLINE : This randomize , double-blind , placebo-controlled study . Participants randomize 1 2 treatment arm . - Arm I : Participants apply 4-hydroxytamoxifen gel 4 metered dos daily breast begin first day cessation first menstrual period digital mammography perform . - Arm II : Participants apply placebo gel arm I . In arm , treatment continue 1 year . In arm , participant collect daily saliva sample 4 menstrual cycle study . Three saliva collection occur cycle encompass time period image study perform ( month 0 , 6 , 12 ) . The fourth collection take place first month gel apply breast . Participants also undergo digital mammography baseline , 6 month , 1 year . Participants develop clinical breast problem consider suspicious cancer discontinue study treatment histological diagnosis establish . Those find breast cancer remove study benign disease continue study . If excisional biopsy perform , density measurement make opposite breast . Quality life assess baseline , 1 month , 6 month , 1 year . PROJECTED ACCRUAL : A total 100 participant ( 50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Afimoxifene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Premenopausal determine menstrual history change menstrual pattern within past 6 month Undergoing mammography least annually No prior breast cancer No clinical breast abnormality suspicious cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 30 50 Sex Female Menopausal status See Disease Characteristics Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective barrier contraception No medical psychiatric disorder would preclude give informed consent PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 3 month since prior oral contraceptive estrogen progesteronecontaining drug No prior tamoxifen 1 month duration No concurrent oral contraceptive estrogen progesteronecontaining drug No concurrent antiestrogen medication Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>breast cancer</keyword>
</DOC>